Melatonin Receptor 1A (MTNR1A, also known as MT1) is a high-affinity G protein-coupled receptor (GPCR) that plays a critical role in mediating the physiological effects of melatonin. Primarily coupling to Gi/o proteins to inhibit adenylyl cyclase activity, MTNR1A is a key target in sleep disorders, circadian rhythm disruption, depression, anxiety, and neurodegenerative pathologies. Developing selective therapeutics requires robust conformational assays and precise counter-screening strategies against its close homolog, MTNR1B.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MTNR1A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MTNR1A Recombinant Protein Sequence Verified. Theoretical MW. Endotoxin Controlled. High Purity (>95%). Suitable for binding studies. |
View MTNR1A Products |
| Gene Delivery | MTNR1A Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Preserves native 7-transmembrane conformation. |
View MTNR1A Products |
| Validator | MTNR1A siRNA Set For knockdown verification and target specificity validation. |
View MTNR1A Products |
| Related Target A | MTNR1B (Melatonin Receptor 1B) Critical homolog for selectivity screening to prevent off-target cardiovascular or metabolic effects. |
View MTNR1B Products |
| Related Target B | GNAI1 (G Protein Subunit Alpha I1) Primary downstream coupling partner for functional Gi-protein signaling assays. |
View GNAI1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation Preservation | Lentivirus-mediated stable cell line construction ensuring native 7-transmembrane folding for functional assay execution. |
| Subfamily Off-target Screening (MT1 vs MT2) | Parallel availability of sequence-verified MTNR1A and MTNR1B reagents for comparative selectivity profiling. |
| Lack of Controls | Validated positive control reagents and sequence-verified reference vectors included. |
| False Positives | Validated siRNA sets included for specific knockdown and background signal subtraction. |
Live MTNR1A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MTNR1A therapeutics is intensifying, with major players shifting focus from traditional non-selective melatonin receptor agonists to highly selective small molecules and emerging biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting biased signaling pathways to separate sleep-promoting efficacy from metabolic and cardiovascular side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Selective Agonist) | Takeda, Vanda Pharmaceuticals | Insomnia, Non-24-Hour Sleep-Wake Disorder | Selectivity Assay (Need MTNR1A vs MTNR1B cell lines) |
| Biased Agonists | Academic Institutes, Biotech Startups | Major Depressive Disorder (MDD), Anxiety | Functional GPCR assays (Need Lentivirus for Stable Cell Lines) |
| GPCR-Targeting Antibodies | Biotech Innovators | Neurodegenerative Diseases, Oncology | Conformational epitope binding (Need cell-based expression systems) |